Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple drug reduce retained placenta after pregnancy termination?

NCT ID NCT02969447

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving oxytocin after a second-trimester medical pregnancy termination helps prevent retained placenta. Twenty-seven women were randomly assigned to receive either oxytocin or no additional medication. The main goal was to see if oxytocin lowers the chance of needing further procedures to remove the placenta.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oxytocin
What this could lead to
If effective, this could provide a simple way to lower the chance of retained placenta after second-trimester pregnancy termination, reducing the need for additional procedures.
What could go wrong
This is a small, single-center trial with only 27 participants, so results may not apply broadly. The benefit may be modest or not statistically significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2016

Finished

Aug 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old and older * medical pregnancy termination between 14 and 28 weeks gestation * informed consent obtained Exclusion Criteria: * less than 18 years old * refusal to consent * in utero fetal death

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retained placenta are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Placenta, Retained

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retained placenta

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33076, France